Patent Office throws out Molecular Biosystems' contrast claims
This article was originally published in Clinica
Executive Summary
The US Patent Office has rejected some of the patent claims contested by Molecular Biosystems and its marketing partner, Mallinckrodt, against ImaRx and Dupont Merck Pharmaceutical. Last August MBI attacked the patents held by a number of rival companies in the microsphere ultrasound contrast agent market. The move was seen as a marketing ploy in this fiercely contested and potentially lucrative business sector.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.